Impact BioMedical Announces Reverse Stock Split To Advance Merger With Zoar Ltd.
Impact BioMedical (IBO) will execute a 1-for-12.62 reverse stock split on September 23, 2026, to facilitate its merger with Zoar Ltd. The split aims to meet listing standards and support the merger, which will give IBO shareholders one Zoar share for every four IBO shares held. IBO's stock closed at $0.46 on September 11, 2026, and was at $0.43 in pre-market trading.
How this was made

The 30-second read
Why it matters
The reverse split is a corporate action required for listing compliance and to align share structures before the merger.
Market read
The announcement provides a concrete catalyst for IBO's stock, creating short‑term trading opportunities around the split date.
What to watch
Potential regulatory hurdles for the merger and the impact of the new CUSIP on market perception.
Background
Impact BioMedical is a micro‑cap biotech listed on NYSE American; Zoar Ltd. is a private pharma partner.
Ticker impact
Impact BioMedical announced a 1-for-12.62 reverse stock split effective Sep 23, 2026 as part of its merger with Zoar Ltd.
Short-term price volatility expected; potential modest upside if split improves compliance perception.
Reverse splits are typically neutral to slightly positive for micro‑caps when tied to a merger, but the effect depends on execution and market sentiment.
Market effects
May signal consolidation in specialty pharma manufacturing sector.
Limited to US micro‑cap biotech investors.
Low; primarily affects Impact BioMedical shareholders.
Counterpoint
The split could be a red flag of underlying weakness, prompting short sellers.
Key entities
- companyImpact BioMedical Inc.
US‑listed biotech pursuing merger with Zoar Ltd.
- companyZoar Ltd.
Pharma manufacturing partner in the proposed merger.


